Why the study?
The ability of oral poliovirus vaccine to regain replication fitness and establish new epidemics represents a significant risk of polio re-emergence should immunization cease.
The engineering of the nOPV2 vaccine strain improves genetic stability and reduces the risk of virulence reversion compared to the original Sabin2 strain, potentially aiding in complete poliovirus eradication.
Answers are grounded in this paper and cite their sources.
Supports next steps in polio vaccine development; leaves open clinical translation from animal models.
The live-attenuated oral poliovirus vaccine (OPV or Sabin vaccine) replicates in gut-associated tissues, eliciting mucosa and systemic immunity. OPV protects from disease and limits poliovirus spread. Accordingly, vaccination with OPV is the primary strategy used to end the circulation of all polioviruses. However, the ability of OPV to regain replication fitness and establish new epidemics represents a significant risk of polio re-emergence should immunization cease. Here, we report the development of a poliovirus type 2 vaccine strain (nOPV2) that is genetically more stable and less likely to regain virulence than the original Sabin2 strain. We introduced modifications within at the 5' untranslated region of the Sabin2 genome to stabilize attenuation determinants, 2C coding region to prevent recombination, and 3D polymerase to limit viral adaptability. Prior work established that nOPV2 is immunogenic in preclinical and clinical studies, and thus may enable complete poliovirus eradication.
No takes yet. Share an insight, caveat, or question.
Yeh et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: